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Abstract: The gastrointestinal tract harbours the largest population of mast cells in the body;
this highly specialised leukocyte cell type is able to adapt its phenotype and function to the
microenvironment in which it resides. Mast cells react to external and internal stimuli thanks
to the variety of receptors they express, and carry out effector and regulatory tasks by means
of the mediators of different natures they produce. Mast cells are fundamental elements of the
intestinal barrier as they regulate epithelial function and integrity, modulate both innate and adaptive
mucosal immunity, and maintain neuro-immune interactions, which are key to functioning of the
gut. Disruption of the intestinal barrier is associated with increased passage of luminal antigens
into the mucosa, which further facilitates mucosal mast cell activation, inflammatory responses,
and altered mast cell–enteric nerve interaction. Despite intensive research showing gut dysfunction
to be associated with increased intestinal permeability and mucosal mast cell activation, the specific
mechanisms linking mast cell activity with altered intestinal barrier in human disease remain unclear.
This review describes the role played by mast cells in control of the intestinal mucosal barrier and
their contribution to digestive diseases.
Keywords: intestinal barrier function; mucosal mast cells
1. Introduction
Mast cells develop a fundamental defensive and immuno-regulatory function, particularly at
the mucosal border between the body and the environment. The intestinal mucosa is the largest
interface that separates the inner and outer environments constantly exposed to luminal content.
It allows only small amounts of antigens and bacteria to cross the epithelium, while preventing the
Cells 2019, 8, 135; doi:10.3390/cells8020135 www.mdpi.com/journal/cells
Cells 2019, 8, 135 2 of 24
passage of potentially harmful substances. The ability to protect the body from harmful luminal
content and control mucosal permeability constitutes the intestinal barrier function. This defensive
function is highly regulated by immune and non-immune mechanisms, in which mast cells play
a central role. Thanks to their great variety of receptors, mast cells respond to different types of
stimuli, including microbial, neural, immune, hormonal, metabolic and chemical triggers. Mast cell
response is vehiculised by the release of mediators contained in their cytoplasmic granules and lipid
bodies or synthesised de novo [1], thereby exerting antimicrobial, neurological, immune and metabolic
functions. Specifically, in the intestinal mucosa, mediators released by mast cells affect epithelial
integrity and viability, promote ion and water secretion, stimulate innate and adaptive immune
responses, blood flow, coagulation and vascular permeability, wound healing and fibrosis, and facilitate
neuro-immune interactions which promote peristalsis and pain perception [2]. Normal functioning of
the intestinal barrier is fundamental for homeostasis, while uncontrolled barrier mechanisms might
lead to enhanced mucosal permeability and passage of luminal antigens and/or microorganisms
across the intestinal epithelium, which potentially induce disturbances in epithelial–neuro-immune
interactions that facilitate the development of inflammation in the gut. In fact, impaired epithelial
barrier function has been largely implicated in the origin and development of many digestive and
non-digestive diseases. Therefore, the tight regulation of intestinal permeability represents a central
mechanism in the treatment and prevention of human disease.
Different methodological approaches have revealed an increased number of mast cells in the
intestinal mucosa of patients with altered barrier function such as in inflammation-associated intestinal
diseases and functional gastrointestinal disorders. Moreover, specific studies have shown a higher
degree of activation of mucosal mast cells by means of the quantification of mast cell mediators and/or
morphological analysis of the degranulation profile of cytoplasmic granules. Stabilising or blocking
mast cell receptors provide, therefore, a promising tool to target disturbances in intestinal permeability
and promote intestinal homeostasis. This review summarises the role of gastrointestinal mast cells in
the regulation of intestinal barrier function and updates advances in the study of disease mechanisms
associated with gastrointestinal diseases.
2. Origin, Phenotype and Function of Gastrointestinal Mast Cells
Mast cells are long-lived granulated immune cells that reside in all vascularised tissues in the
body. They derive from haematopoietic stem cells, which generate progenitor mast cells that circulate
in low numbers in the blood and migrate to tissues in which they complete their differentiation
process [2,3]. Their function, maturation and phenotype are the direct consequence of their interaction
with the local microenvironment, including the production of a wide variety of membrane molecules
involved in cell-to-cell or cell-to-extracellular matrix interaction [4], although pleiotropic, mast cells
preferably reside in mucosal interfaces (skin, respiratory, genito-urinary and gut mucosa) in close
contact with the environment, ready to react against infectious organisms, harmful substances and
other environmental challenges. Intestinal homing of mast cells depends on the binding of α4β7
integrin with its corresponding adhesion molecules and the CXC chemokine receptor-2, both expressed
in gastrointestinal mast cells [5]. Depending on the anatomical location, mast cells are categorised
into connective tissue mast cells or mucosal mast cells. Based on their protease content, mast cells are
classified as: mast cells containing high levels of tryptase but little or no chymase (MCT), mast cells
containing chymase but little or no tryptase (MCC) and mast cells containing tryptase, chymase
and carboxypeptidase (MCTC) [6]. However, mast cell classification based on protease content is
ambiguous, since protease expression can change depending on the tissue environment.
Mast cells can be found in all layers within the gastrointestinal tract; however, the largest
population resides in the lamina propria of the mucosa and in the submucosa. Specifically, MCT are
predominant in the intestinal mucosa (98%), while representing only 13% of all mast cells in the
submucosa [7]. By contrast, MCTC is the main phenotype in the intestinal submucosa, accounting for
77%, while the rest of the population displays an MCT phenotype [8]. MCC have also been identified but
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appear to be uncommon [6]. A new phenotype of mast cells expressing tryptase and carboxypeptidase
A3, but not chymase, has recently been defined in the bronchial and oesophageal mucosa associated
with the pathophysiology of asthma and eosinophilic oesophagitis, respectively [9,10]. However,
exactly how this phenotype contributes to human disease remains unknown.
Mast cells are currently recognised as regulatory and effector cells in both innate and adaptive
immunity. Their broad functions rely on their ability to react to a great variety of stimuli and secrete
biologically-active products with pro-inflammatory, anti-inflammatory and/or immunosuppressive
properties. Mast cells play a prominent role in immunoglobulin(Ig)-mediated allergic inflammation,
and are also involved in a variety of intestinal and non-intestinal diseases such as gastrointestinal
inflammation, functional gastrointestinal disorders, infections, autoimmune diseases, atherosclerosis
and carcinogenesis [11] as well as in neuropsychiatric conditions [12]. Of importance for intestinal
homeostasis, mast cells are fundamental for diverse intestinal physiological processes such as the
regulation of mucosal integrity and epithelial barrier activity, and the maintenance of neuro-immuno
interaction that supports the brain-gut axis. The fact that mast cells have persisted throughout
vertebrate evolution, with an ancient origin even before the development of adaptive immunity,
reinforces their importance in innate immunity as well as their remarkable role in such a variety of
diseases [13].
3. Mast Cell Activation
The surface of mast cells is covered with a variety of receptors specific for immune ligands
(Igs, complement fragments and cytokines) and for non-immune mediators, which include
neurotransmitters, neuropeptides, hormones, growth factors and other biological and physicochemical
stimuli [14]. Mast cell versatility implies they can be activated by different mechanisms,
with cross-linking of IgE high-affinity receptor (FcεRI) to cell surface-bound IgE being the traditional
and best studied stimulus in sensitised individuals [15]. A response is then triggered by a serie of
phosphorylation cascades and activation motifs that lead to intracellular calcium flux, activation
of transcription factors (such as AP-1, MITF and STAT-5), mast cell degranulation and cytokine
production [16]. Mast cells can additionally be stimulated by IgG since they also express its receptor
(FcγRI) [17] and other Ig-associated receptors. Of importance for the control of gastrointestinal
disease is the recently identified IgG signalling via FcγRIIb, which suppresses a hypersensitivity
reaction [18]. As innate immune sentinels, mast cells recognise microbial agents (bacterial, viral,
parasitic and fungal) and endogenous factors derived from cell damage by germline-encoded pattern
recognition receptors, which include toll-like receptors (TLRs), C-type lectin-like receptors (CLRs),
retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) and nucleotide-binding oligomerisation
domain (NOD)-like receptors (NLRs) [19]. Importantly for homeostasis and for ensuring an appropriate
response to injury, mast cells also respond to different endogenous stimuli since they express receptors
for neurotransmitters (such as acetylcholine and serotonin), neuropeptides (such as substance P, SP and
vasoactive intestinal peptide, VIP), neurotrophins (such as nerve growth factor, NGF) and gaseous
neurotransmitters (such as nitric oxide, NO).
Upon activation, mast cells release biologically-active products (Table 1), newly synthesised or
already contained in their cytoplasmic granules and lipid bodies [1]. The storage of these molecules in
mast cell granules is possible, thanks to the anionic gel matrix composed of heparin and chondroitin
sulphate, in which the mediators become trapped [20]. Pre-formed mediators include proteases,
biogenic amines, proteoglycans, lysosomal enzymes, certain cytokines and growth factors and
granule membrane-associated proteins. Newly-synthesised mediators include lipidic compounds,
neuropeptides and a huge variety of cytokines, chemokines and growth factors [1,21]. This wide variety
of molecules produced by mast cells supports their pleiotropic functions during both homeostasis
and disease.
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Table 1. Mast cell mediators.
Pre-Formed Mediators
Proteases Mast cell-specific: tryptase, chymase, carboxypeptidase A
Non-mast cell-specific: cathepsin G, granzyme B, active caspase 3, ADAMTS5, renin
Biogenic amines Histamine, serotonin, dopamine, polyamines
Proteoglycans Serglycin, chondroitin sulphates, heparin
Lysosomal enzymes β-hexosaminidase, β-glucuronidase, arylsulphatase, cathepsins
Cytokines/growth factors TNF, IL-4, GMCSF, bFGF, VEGF, NGF
Granule membrane-associated proteins VAMPs, syntaxin 3, synaptotagmins, MUNCs, SCAMPs, CD63, RABs, LC3-II, MHC class II
Others Heparanase, CAP-18, secretogranin-III and chromogranin A
Newly-Synthesised Mediators
Lipid mediators Leukotriene C4/B4, prostaglandin D2, platelet-activating factor
Cytokines IL-1, IL-3, IL-6, IL-18, TNF, SCF, TGF-β
Chemokines MCP-1, RANTES, eotaxin, TARC
Growth factors GMCSF, MCSF, bFGF, PDGF, NGF, VEGF, GnRH
ADAMTS5, a disintegrin and metalloproteinase with thrombospondin motifs 5; TNF,
tumour necrosis factor; IL, interleukin; GMCSF, granulocyte-macrophage colony-stimulating factor;
bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; NGF, nerve growth
factor; VAMP, vesicle-associated membrane protein; MUNC, mammalian uncoordinated-18
protein; SCAMP, secretory carrier-associated membrane protein; LC3, lipidated light chain 3;
MHC, major histocompatibility complex; CAP, cathelicidin antimicrobial peptide; SCF, stem cell factor;
TGF, transforming growth factor; MCP, monocyte chemoattractant protein; RANTES, regulated upon
activation normal T-cell expressed and secreted chemokine; TARC, thymus and activation-regulated
chemokine; MCSF, macrophage colony–stimulating factor; PDGF, platelet-derived growth factor; GnRH,
gonadotropin-releasing hormone.
The secretion of mast cell mediators is carried out mainly by two mechanisms: piecemeal and
anaphylactic degranulation (Figure 1). Piecemeal degranulation leads to partial or total granule
emptying, causing a selective release of the content without inter-granule or granule-to-plasma
membrane fusions. Ultrastructural analysis showed granule morphology to be quite conserved
after the piecemeal process [22]. This type of secretion is promoted by neuropeptides, cytokines and
microbial products that interact with mast cells, as described in physiological conditions and a variety of
digestive diseases, among which inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and
functional dyspepsia (FD) have been the most studied [23–25]. By contrast, anaphylactic degranulation
is the explosive release of mast cell content by granule or granule-to-plasma membrane fusions
followed by extrusion [26] and is associated with hypersensitivity reactions. Mast cell degranulation is
mediated by the soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARES),
of which VAMP-7, VAMP-8, SNAP-23 and STX-4 have been reported to be significant SNARE molecules
in human intestinal mast cell granule fusion and exocytosis [27,28]. The degree and type of activation
of mast cells, as a consequence of their interaction with the microenvironment, determines the
maintenance of homeostasis or disruption of essential defensive functions in the mucosa. This is
of key importance for intestinal physiological activity, since the intestine represents the largest surface
of the body in contact with the external environment and mast cells interact with virtually all cells in the
mucosa as well as with microorganisms and harmful molecules that reach the intestine. Cell plasticity
and responsiveness define mast cells as a fundamental component of intestinal barrier function during
both homeostasis and disease.
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Figure 1. Intestinal mucosal mast cells. Representative micrographs of human mast cells showing 
different morphology at the ultrastructural level. (A) Resting mast cell with intact cytoplasmic 
granules and lipid bodies, displaying regular plasma cell membrane. (B) Activated mast cells showing 
piecemeal degranulation with loss of intra-granular electrodensity (black arrow) and inter-granular 
or granule-to-cell membrane fusion and typical channels (white arrow) during anaphylactic 
degranulation. Magnification 12,000×. 
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The surface of the intestinal mucosa is lined with epithelial cells, which physically separate the 
intestinal lumen from the internal milieu, thereby avoiding the passage of potentially harmful 
substances while maintaining nutrient and electrolyte absorption. During evolution, the gut 
developed the intestinal barrier function, an effective defensive system involving intra-and 
extracellular elements, which closely interact to promote correct functioning of the epithelium, 
immune responses and acquisition of tolerance against food antigens and the intestinal microbiota. 
The loss of epithelial integrity facilitates antigen penetration into the mucosa, which triggers 
immunological responses which, in turn, increase epithelial permeability to luminal content, thereby 
promoting inflammation. An abnormal intestinal barrier has major implications for human health, 
being involved in the origin and development of many digestive (coeliac disease, IBD, IBS, food 
allergy) and extra-digestive diseases (schizophrenia, diabetes and sepsis, among others) [29,30]. The 
role of mast cells in intestinal barrier control is well documented; however, the specific mechanisms 
by which mast cells contribute to barrier dysfunction in human disease remain unclear.  
4.1. Elements of Intestinal Barrier Function 
The intestinal barrier is composed of different elements, located in both the luminal and internal 
compartments. Residing in the lumen, the microbiota restricts pathogen colonisation and interacts 
with epithelial, immune and neural cells [31] to promote barrier function by mechanisms that include 
nutrient acquisition, energy and metabolism regulation [32,33], and cell proliferation [34]. 
Extracellular luminal elements include pH, enzymes from gastric, pancreatic and biliary secretions, 
the mucus layer and molecules released by epithelial and immune cells, which include defensins, 
lisozyme, phospholipids, trefoil factor family peptides, cathelicidins, ribonucleases and Igs, mainly 
secretory IgA [35,36]. Furthermore, peristaltism and water and chlorine secretion into the lumen 
wash out content and slow down antigen translocation to the lamina propria [37]. The epithelial layer 
is a fundamental and multifunctional element of the barrier responsible for barrier, digestive, 
metabolic and immune functions [37]. The epithelium includes specialised cells that produce and 
secrete mucus (goblet cells), defensins (Paneth cells), hormones and neuropeptides (enterochromaffin 
cells). It also includes a unique cell type specialised in antigen uptake from the lumen (M cells) [38]. 
Fig re 1. I testi al cosal ast cells. e rese tative icrogra s of a ast cells s o i g
iffere t r l at t e ltrastr ct ral le el. ( ) esti ast cell it i tact c t las ic
r l s li i i s, is l i r l r l s c ll r . ( ) cti t st c lls s i
i l r lation ith los of intra-granular el ctrodensity (black arrow) and inter-granular or
g anule-to-cell membrane fusion and typical channels (white arrow) during anaphylactic degranulation.
Magnific 12,000×.
4. Intestinal Barrier Function
The surface of the intestinal mucosa is lined with epithelial cells, which physically separate
the intestinal lumen from the internal milieu, thereby avoiding the passage of potentially harmful
substances while maintaining nutrient and electrolyte absorption. During evolution, the gut developed
the intestinal barrier function, an effective defensive system involving intra-and extracellular elements,
which closely interact to promote correct functioning of the epithelium, immune responses and
acquisition of tolerance against food antigens and the intestinal microbiota. The loss of epithelial
integrity facilitates antigen penetration into the mucosa, which triggers immunological responses
which, in turn, increase epithelial permeability to luminal content, thereby promoting inflammation.
An abnormal intestinal barrier has major implications for human health, being involved in the origin
and development of many digestive (coeliac disease, IBD, IBS, food allergy) and extra-digestive
diseases (schizophrenia, diabetes and sepsis, among others) [29,30]. The role of mast cells in intestinal
barrier control is well documented; however, the specific mechanisms by which mast cells contribute
to barrier dysfunction in human disease remain unclear.
4.1. Elements of Intestinal Barrier Function
The intestinal barrier is composed of different elements, located in both the luminal and internal
compartments. Residing in the lumen, the microbiota restricts pathogen colonisation and interacts
with epithelial, immune and neural cells [31] to promote barrier function by mechanisms that include
nutrient acquisition, energy and metabolism regulation [32,33], and cell proliferation [34]. Extracellular
luminal elements include pH, enzymes from gastric, pancreatic and biliary secretions, the mucus
layer and molecules released by epithelial and immune cells, which include defensins, lisozyme,
phospholipids, trefoil factor family peptides, cathelicidins, ribonucleases and Igs, mainly secretory
IgA [35,36]. Furthermore, peristaltism and water and chlorine secretion into the lumen wash out
content and slow down antigen translocation to the lamina propria [37]. The epithelial layer is a
fundamental and multifunctional element of the barrier responsible for barrier, digestive, metabolic
and immune functions [37]. The epithelium includes specialised cells that produce and secrete mucus
(goblet cells), defensins (Paneth cells), hormones and neuropeptides (enterochromaffin cells). It also
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includes a unique cell type specialised in antigen uptake from the lumen (M cells) [38]. To ensure an
effective physical barrier, epithelial cells are tightly bonded to each other by intercellular junctions
(tight junctions, TJ, at the apical junctional complex, followed by adherent junctions, and desmosomes).
The immune contribution to the mucosal barrier is carried out by the gut-associated lymphoid
tissue (GALT) distributed in organised lymphoid structures such as lymphoid follicles, Peyer’s patches
and mesenteric lymph nodes, in which immune responses are initiated. GALT also includes a diffuse
distribution of effector cells throughout the epithelium and the lamina propria of the intestinal
mucosa [39], composed mainly of plasma cells, macrophages, mast cells, lymphocytes, eosinophils
and dendritic cells [40]. Furthermore, connective tissue, blood and lymph vessels and fibroblasts
that reside in the lamina propria also contribute to barrier function maintenance. An integrated
network of neural cells from both the central and enteric nervous systems coordinates digestive
functions and intestinal homeostasis maintenance via the release of neurotransmitters and, indirectly,
neuro-immune interactions.
4.2. Mast Cells as Neuro-Immune Players in the Regulation of Intestinal Barrier Function
Control of the intestinal barrier results from a network of interactions among the microbiota,
epithelial cells and immune and nervous systems. The communication between the central and enteric
nervous systems, the so-called brain-gut axis, permits regulation of the intestinal barrier by monitoring
ion secretion, epithelial tightness, immune function and peristalsis. The functional unit established by
mast cell-nerve interaction [41] is a fundamental component in such interplay via paracrine signalling
(the most common), transgranulation (granule fragments and mediators are delivered directly to the
neuronal body) and integrin signalling (physical synapses through integrins) [21]. Enteric neurons,
as well as vagal and spinal afferents, express receptors for molecules (mainly proteases, neuropeptides,
hormones and growth factors) released by mast cells, which stimulate nerve terminals, thereby
modulating the firing threshold. Similarly, neuropeptides and neurotransmitters released by neurons
stimulate mast cell secretion of mediators, which further activate neuronal receptors [21], supporting
the maintenance of this neuro-immune interplay. This interaction contributes to monitoring of gut
function by the central nervous system; however, if overstimulated, it can exert harmful effects
associated with disease [42].
The contribution of mast cells to barrier function through neuro-immune mechanisms has
been evidenced in different experimental settings. Diverse stressors (physical and psychological,
acute and chronic) have been shown to disturb barrier homeostasis by increasing ion secretion and
epithelial permeability [43,44], effects avoided in mast cell knock-out rats and also in humans after
oral pretreatment with a mast cell stabiliser [45,46]. The stress response, which includes endocrine
and behavioural changes, is centrally mediated by the release of corticotropin-releasing factor (CRF).
Additionally, intestinal mucosal cells, including immunocytes, nerves and enterochromaffin cells,
produce and release CRF upon activation. Local CRF interacts with its receptors (CRF-R1, CRF-R2) on
subepithelial mast cells [47] to induce mucin release, ion and water secretion, and increase epithelial
permeability [46,48,49]. Moreover, other neuropeptides such as SP and NGF induce the release of
vasoactive mediators from mast cells, thereby contributing to chloride secretion, barrier dysfunction,
hyperalgesia, diarrhoea, inflammation and motility changes [50]. In fact, epithelial permeability to
luminal bacteria seems to be modulated by VIP and mast cell activity, as suggested by the VIP–mast
cell-dependent regulation of commensal and pathogenic bacteria passage in the human colon [51].
5. Regulation of Intestinal Mucosal Barrier by Mast Cells
Mast cells are unique due to their ability to modulate their phenotype, a process called
transdifferentiation [52] by which they synthesise and release a specific mediator profile depending
on the microenvironment [53]. The anatomical complexity of the intestine and the ever-changing
environment contribute to mast cell phenotype which, based on the nature of mediators released into
the extracellular milieu, determines organ function. In this way, intestinal mast cells perform multiple
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functions necessary for homeostasis, including the regulation of epithelial activity (ion and water
secretion and permeability), endothelial functions (blood flow, coagulation and vascular permeability),
tissue transformation (wound healing and fibrosis), neurological functions (neuro-immune interactions,
peristalsis and pain perception), host defence (bacterial, viral and parasitic infections) and innate and
adaptive immunity [2] (Figure 2). The most prominent contributions of mast cells to mucosal barrier
control are mediated through mechanisms that modulate epithelial function and innate and adaptive
defensive responses.
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5.1. Regulation of Epithelial Function
Among the large variety of molecules released by mast cells, evidence of their contribution to
epithelial integrity stems from studies designed to reveal the role of proteases, histamine and cytokines
(Table 2).
5.1.1. Tryptase
This enzyme is the most abundant secretory granule-derived serine proteinase contained in mast
cells and has been largely implicated in epithelial permeability. It activates a protease-activated receptor
(PAR2) [54], expressed on both the apical and basolateral membranes of intestinal epithelial cells,
promoting TJ disruption and increasing intestinal permeability [55]. Tryptase cleavage and activation
of PAR2 lead to calcium mobilisation, beta-arrestin and ERK1/2 MAPK activity, perijunctional F-actin
redistribution [56,57], Zonula-1 (ZO-1) delocalisation [58] and protein junctional adhesion molecule-A
(JAM-A) downregulation [59]. Tryptase is also able to damage cells, as interpreted by a reduction in
cell viability together with an increase in lactate dehydrogenase activity and apoptosis [57].
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5.1.2. Chymase
This chymotrypsin-type serine protease is implicated mainly in extracelluar matrix degradation
and also targets epithelial integrity through activation of the PAR2 receptor. The biological function of
chymase has been studied through the generation of mouse strains deficient in different murine mast
cell proteases (mMCP), functional homologues to human chymase: mMCP-1 mMCP-2 mMCP-4 or
mMCP-5 [60]. Experimental studies have shown that the activation of PAR2 receptors by chymase
induces p38 phosphorylation and p44/42 (ERK1/2) signalling pathway activation, which increase
metalloprotease-2 (MMP-2) and reduce claudin-5, resulting in epithelial barrier dysfunction [61].
Specifically, the rat mucosal mast cell chymase, rMCP-2, increases epithelial permeability through
alteration of ZO-1 and occludin distribution in epithelial cells [62] and cleavage of occludin, cadherin
17 and protocadherin alpha [63].
5.1.3. Histamine
This amine is a preformed mast cell mediator involved in a variety of physiological and
pathological processes throughout the gastrointestinal tract. It mediates immunological responses,
visceral nociception, modulation of intestinal motility and gastric acid secretion through activation of
its receptors (H1-H4) [64]. The contribution of histamine to epithelial dysfunction is mediated by H1
receptors directly stimulating chloride secretion, as demonstrated in the human colonic epithelium [65].
Recent evidence also revealed a role of histamine in increasing epithelial intestinal permeability and
bacterial translocation in malaria-infected mice [66]; however, the specific mechanisms leading to
barrier deregulation remain unknown.
5.1.4. Cytokines
These small molecules are released mainly by lymphocytes, macrophages, eosinophils, dendritic
cells and mast cells that mediate inter-cell communication. Mast cells produce a large variety
of cytokines, many of which have a direct impact on the intestinal epithelial barrier (Table 2).
TNF-α directly disrupts TJ via myosin light-chain kinase (MLCK)-mediated phosphorylation of
the myosin light chain (MLC) [67,68] and ZO-1 and occludin downregulation [68,69]. Interleukin
(IL)-4 stimulates mast cell IL-13 production [70], with both molecules sharing the IL-4Rα chain
receptor, which elicits phosphatidylinositol 3-kinase (PI3K) activation and modulation of epithelial
paracellular permeability [71]. IFN-γ also alters paracellular permeability in the intestine through
the reduction of claudin 2 and 3 and reorganisation of claudin 4 [72]. IL-1β regulates intestinal
function mainly via activation of the NF-κB pathway and the MLCK gene [73–75]. IL-9 also increases
intestinal permeability associated with a genetic profile identified in intestinal anaphylaxis [76],
and IL-6 promotes JNK activation of AP-1 and upregulation of the claudin 2 gene, leading to TJ
disruption [77]. On the other hand, the anti-inflammatory cytokine IL-10 has also been shown
to develop a protective role in intestinal barrier function, since IL-10-gene-deficient mice showed
increased intestinal permeability [78,79] and the administration of IL-10 prevented IFN-γ-induced
barrier dysfunction [80]. However, IL-10 has been shown to enhance IgE-mediated mast cell activity,
which suggests a potential contribution to barrier dysfunction during food allergy response [81].
5.2. Regulation of Mucosal Immunity
A multivalent capacity to recognise and respond to both internal and external dangers,
together with the ability to cross-talk with other immune cells, render mast cells a unique player
in linking innate and adaptive immunity.
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Table 2. Mast cell mediators and mechanisms associated with epithelial barrier dysfunction.
PROTEASES
Sample Effect/ Implicated Mechanism Ref.
Tryptase
Increased intestinal permeability
T84 intestinal epithelial cell line Activation of PAR2 via ERK1/2 MAPKReorganisation of perijunctional F-actin [56]
IEC-6 rat intestinal epithelial cell line Activation of PAR2 via ERK MAPK [57]
MDCK epithelial cell line Activation of PAR2 via p38-MAPK activationDisruption of tight junctions, relocalisation of ZO-1 [58]
IBS caecum biopsies Reduced JAM-A expression [59]
Chymase
Increased intestinal permeability
Caco-2 intestinal epithelial cell line Activation of MMP-2 signalling through PAR2Reduction in CLDN-5 [61]
MDCK epithelial cell line Effect on the paracellular routeAltered distribution of ZO-1 and OCLN [62]
Phage display analysis for rMCP-2 cleavage specificity rMCP-2 cleaves OCLN, cadherin 17 and protocadherin alpha 4 [63]
HISTAMINE
Human colonic epithelium Epithelial dysfunction/ Stimulates chloride secretion [65]
Antihistamine treatment in mice with malaria Reduced gut permeability and bacterial translocation [66]
CYTOKINES
Increased intestinal permeability
TNF-α
Caco-2 intestinal epithelial cell line Opening of the intestinal barrier TJNF-kB p50/p65 binding and activation of the MLCK promoter [67]
Caco-2 and T84 intestinal epithelial cell line
Transepithelial resistance decreased
MLC phosphorylation promotes TJ disruption
Decreased expression of ZO-1 and OCLN
[68]
Human intestinal cell lines HT-29/B6 Downregulation of OCLN [69]
IL-4 and IL-13 T84 intestinal epithelial cell line Decreased transepithelial resistance via PI3K pathway [71]
IFN γ T84 intestinal epithelial cell line Decreases in CLDN-2 and 3Redistribution of CLDN-4 [72]
IL-1β
Caco-2 intestinal epithelial cell line Activation of NF-kB pathways [73]
Caco-2 intestinal epithelial cell line Activation of the NF-κB pathway and the MLCK gene [74]
Human corneal epithelial cells
Loss of corneal epithelial barrier function
Dependent on NF-κB
Redistribution of ZO-1 and OCLN
[75]
IL-9 IL-9 overexpression in mice Decrease in transepithelial electrical resistanceIncrease in jejunal permeability to FITC-dextran and HRP [76]
IL-6 Caco-2 intestinal epithelial cell lineMouse intestinal perfusion JNK activation of AP-1 and upregulation of CLDN-2-gene [77]
Protective role in intestinal barrier function
IL-10
IL-10 gene-deficient mice Increased intestinal permeability [78,79]
Human endothelial solute barrier Blockage of IFNγ-induced epithelial permeability [80]
PAR2, protease-activated receptor-2; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein
kinase; MDCK, Madin-Darby canine kidney; ZO-1, zonula occludens-1; IBS, irritable bowel syndrome; JAM-A,
junctional adhesion molecule-A; MMP-2, matrix metalloproteinase-2; CLDN, claudin; OCLN, occludin; rMCP,
rat mast cell protease; TJ, tight junctions; NF-kB, nuclear factor-kappa B; MLCK, myosin light-chain kinase; MLC,
myosin light chain; PI3K, phosphoinositide 3-kinase; IL, interleukin; HRP, horseradish peroxidase; FITC, fluorescein;
JNK, c-Jun N-terminal kinase; AP, activator protein; IFN, interferon.
5.2.1. Mast Cells in Innate Immune Responses
Innate immunity constitutes the first line of defence against invading pathogens and performs
an essential task prior to the development of adaptive immunity. Mast cells play a protective role
against bacterial and viral infections via mechanisms that include the recruitment of neutrophils,
eosinophils and macrophages to the mucosa [82] and the activation of defensive responses (Table 3).
Mast cells release phospholipase A2 and extracellular enzymes with proinflammatory and antibacterial
activities [83]. These enzymes exert a direct killing effect on pathogens through mast cell extracellular
traps (MCET), which consist of extracellular extensions/fibres composed of DNA, histones, proteases,
tryptases and anti-microbial peptides. MCET are actively formed by mast cells when they are not
able to exert efficient phagocytosis of clumped bacteria. MCET formation relies on the production of
reactive oxygen species and culminates in the death of mast cells [84]. MCET formation seems to be
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induced by hypoxic stress, thanks to the hypoxia-inducible factor 1α (HIF-1α) [85], but also by the
increase in cytokines such as IL-23 and IL-1β [86]. Specific bacterial proteins such as Streptococcus
pyogenes M1 protein also appear to activate this mast cell response [87]. A further mechanism by
which mast cells participate in innate immunity is phagocytosis. The phagocytic activity displayed by
mast cells against some bacteria (e.g., Klebsiella Pneumoniae, Escherichia Coli, Streptococcus faecium,
Citrobacter freundii) [88] could be mediated by different mechanisms: through the surface complement
receptors that detect and opsonise bacteria [89] or the recognition of bacterial Fim-H adhesins, via CD48
receptors [90]. Antimicrobial peptides released by mast cells include cathelicidins, which also act as
leukocyte chemoattractants through interaction with the Formyl peptide receptor–like 1 (FPRL1) of
leukocytes [84], leading to degranulation of β-tryptase [91] which, in turn, degrades cathelicidin [92].
This suggests that mast cells exert an auto-regulatory autocrine regulation that permits immune
modulation through a negative feedback loop. Mast cell proteases participate in innate immunity
by different mechanisms. Tryptase seems to be essential to fight bacterial infection through the
recruitment of neutrophils [93]. Chymase contributes to inhibiting Streptococcus attachment to the
extracellular matrix via the proteolytic degradation of fibronectin [94] and plays a role in promoting
parasite expulsion [95]. Carboxypeptidase A favours the clearance of endogenous and exogenous
toxins [96,97], and histamine released by mast cells initiates neutrophil infiltration into the colonic
mucosa through H4R, as demonstrated in a murine model of experimental colitis [98].
Table 3. Mast cell implication in innate immunity.
Mast Cell Mediators Target Cell/Molecule Effect/ Implicated Mechanism Ref.
TNFα
Neutrophils
Eosinophils
Macrophages
Recruitment of innate immune cells
Proinflammatory effect [82]
sPLA2 EosinophilsMacrophages
Activation of innate immune cells
Proinflammatory effect [83]
MCTES: Extracellular fibres
composed of DNA, histones,
proteases and AMP
Bacteria Antibacterial effect [84]
Complement receptors Complement attached tobacteria Phagocytosis
Antibacterial effect
[89]
CD48 Bacterial adhesins (Fim-H) [88,90]
AMP:
Cathelicidins Pathogens Antibacterial effect [84]
Tryptase Neutrophil Recruitment Pro-inflammatory effect [93]
Chymase Fibronectin Extracellular matrixdegradation
Inhibition of Streptococcus
attachment to EM [94]
Carboxypeptidase Exogenous toxins Proteolysis Protective effect [96,97]
Endogenous toxins Proteolysis Homeostatic effect
Histamine Neutrophil Recruitment Pro-inflammatoryeffect [98]
TNFα, tumour necrosis factor alpha; sPLA2, phospholipase A2; MCTES, mast cell extracellular traps, DNA,
deoxyribonucleic acid; AMPS, antimicrobial peptides; Fim-H, type 1 fimbrin D-mannose-specific adhesion;
EM, extracellular matrix.
5.2.2. Mast Cells in Adaptive Immune Responses
Adaptive immunity induces specific and memory responses to certain antigens. Mast cells support
T-cell and B-cell activation and provide fine-tuning of tolerance and immune suppression (Table 4).
Interaction with T lymphocytes: mast cells promote activation, recruitment, proliferation
and cytokine secretion in multiple T-cell subsets, although the most well-known interaction is
their involvement in Th2-mediated inflammation associated with allergic disease [99]. Moreover,
close physical proximity between mast cells and T cells has been demonstrated in several
T cell-mediated inflammatory processes. Mast cell have been shown to be activated by T cells,
an effect that is mediated by T cell -derived microvesicles and results in specific proinflammatory
cytokine release [100,101]. Mast cells release a wide variety of chemotactic factors for different CD4+
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T-helper (Th) cell subsets: CCL3, CCL4, CXCL9 and CXCL10 for Th1; CCL5 and CCL11 for Th2;
and CCL2 and CCL20 for Th17 [102]. Furthermore, mast cells also support the polarisation of Th cell
responses through the secretion of specific mediators such as IL-12 and IFNγ for Th1; IL-4 for Th2;
IL-6 and TGFβ1 for Th17; and IL-6 and TNFα for Th22 [103]. Thanks to their pathogen-recognising
receptors, mast cells internalise and process antigens that are presented to T cells by MHC class
II mechanisms [104]. Furthermore, after activation, mast cells secrete TNFα, which binds TNFRI
and TNFRII on T cells to regulate T-cell activation, surface expression of OX40, ICOS, PD-1 and
other co-stimulatory molecules on CD4+ cells, thereby enhancing T-cell proliferation and cytokine
secretion [105]. In addition, mast cells seem to downregulate the suppressive function of T regulatory
cells (Treg) by IL-6, as well as establishing a direct contact through OX40L on mast cell membranes
and the receptor OX40 on the Treg surface receptor [106]. Histamine released by mast cells also
regulates Treg cells; thus, interaction with H1 receptors in Tregs induces a reduction in CD25 and
Foxp3 expression, leading to a decrease in Treg suppressive activity [107].
Interaction with B lymphocytes: mast cells directly support IgE production through the secretion
of IL-4 and IL-13 and the interaction between CD40L and CD40 expressed on mast cells and B cells,
respectively [108]. Moreover, mast cells are also involved in B cell proliferation and differentiation
into IgA-secreting plasma cells by direct interaction (CD40/CD40L) and the secretion of IL-6, IL-5 and
transforming growth factor-β (TGF-β) [109]. Other cytokines released by mast cells, IL-5 and IL-33,
are involved in the production of IgM and play a crucial role in tissue homeostasis and defence
against mucosal pathogens [110]. B lymphocyte survival and proliferation are also influenced by mast
cells through the secretion of cytokines and chemokines, also at distal sites through the release of
exosomes, which contain proteins, RNA, soluble mediators, FcεRI receptors, MHC class II proteins
and co-stimulatory molecules [111]. Exosomes are released and bind to receptors on target cells such
as B cells. Once internalised, messages delivered by exosomes promote the generation of IL-2, IL12,
IFNγ, IgG1 and IgG2 by B cells [112].
Table 4. Mast cell implication in adaptive immunity.
Mast Cell Mediators Target Cell Effect/Implicated Mechanism Ref.
CCL3, CCL4, CXCL9, CXCL10 Th1 Adaptative immune cell recruitment
Pro-inflammatory effect [102]CCL5, CCL11 Th2
CCL2, CCL20 Th17
IL-12, IFNγ Th1
Polarisation of Th responses [103]
IL-4 Th2
IL-6, TGFβ1 Th17
TNFα Th22
MHC class I and II T cells Ag presentationPro-inflammatory effect
[104]
[105]
TNFα T cells ActivationProliferation
[105]
IL-6 Receptors on Treg cells Inhibition
Pro-inflammatory effect [106]OX40L OX40
Histamine H1 receptors Decrease in CD25 expression and Foxp3 transcription in Treg cells [107]
IL-4, IL-13 B cells Class switch recombination into IgE producing plasma cells [108]
IL-6, IL-5, TGFβ B cells Class switch recombination and differentiation into IgAproducing plasma cells [109]
CD40L CD40 receptor on B cells Co-stimulatory signal for Ig class switching [108,109]
IL-5, IL-33 B cells subtype B-1
Stimulation
IgM production.
Participation in homeostasis and pathogen defence response
[110]
Exosomes containing: RNAs,
soluble mediators, FcεRI, MHC II Receptors on B cells Promotion of IL-2, IL-12, IFNγ, IgG1, and IgG2 synthesis [111]
CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; Th, T helper; IL, interleukin;
IFNγ, interferon gamma; TGFβ1, transforming growth factor beta 1; TNFα, tumour necrosis factor alpha; MHC,
major histocompatibility complex; Ag, antigen; Tregs, T regulatory cells; OX40L, OX40 ligand; H1, histamine
receptor type-1; FOXp3, forkhead box P3; CD40L, CD40 ligand; Ig, immunoglobulin; RNA, ribonucleic acid; FcεRI,
high-affinity IgE receptor I.
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6. Experimental Procedures to Evaluate Intestinal Mast Cells
Mucosal mast cell infiltration and activation can be assessed by several methods (Figure 3).
Morphological analysis in tissue specimens is recommended for identifying cell architecture and
mast cell location through simple histochemical dyes (with toluidine blue being the most specific)
or by using antibodies anti-mast cell proteins via immunohistochemistry or immunofluorescence
techniques (tryptase, chymase, c-kit, FcεR1) [113,114]. Mast cell activation can be assessed by analytical
methods quantifying mast cell mediators or metabolites in different biological samples (urine, blood,
luminal content, biopsy, cell suspension, cell culture supernatant). For example, tryptase content in
the intestinal lumen as well as tryptase gene expression in mucosal biopsies have been identified
in activated mucosal mast cells in IBS patients and associated with symptom severity [115,116].
Urinary prostaglandin D2 and leukotriene E4 levels are also raised after mast cell activation, although
the use of the former as a single marker is not recommended and the latter has not been fully
validated. Urinary histamine has been widely used as a specific marker; however, its metabolites
are influenced by diet or bacterial contamination and its concentration in blood can also derive from
basophils and be affected by several factors such as blood sample handling [117]. Since histochemical
staining does not provide information on granule secretion at subcellular level, ultrastructural analysis
is necessary to establish the type and degree of degranulation. Different imaging techniques are
available, with electron microscopy being the most commonly used, since high magnification reveals
cellular and subcellular structure. Transmission electron microscopy allows us to determine whether
mast cells display a secretory profile, type of degranulation, granular and plasma cell membrane
morphology and the proximity to other cells or structures within the tissue. Nevertheless, it has some
limitations since the dehydration of samples or imaging under vacuum can affect cell membranes.
A complementary technique is atomic force microscopy, which preserves structural integrity and
permits cell analysis of high-resolution 3D-generated images. Degranulation of mast cells can be
studied in vivo using a fluorescent protein-based indicator of degranulation named immune-pHluorin
(impH) that identifies changes in fluorescence according to the pH value. The study of secretory
granule biogenesis, maintenance, regulation and recycling can also be analysed using negative contrast
imaging [113]. Gene and protein expression (after sample fixation for RNA/protein stabilisation) has
been analysed to identify a mast cell-associated gene/protein profile or to assess the expression of
specific molecules.
Functional assays can also be performed in different experimental settings to reveal
activation/inhibition mechanisms of mast cells. Different immortalised mast cell lines (LAD-2, HMC-1,
LUVA) or isolated primary cells (blood progenitors or tissue mast cells) are currently being used
individually or in co-culture with other leukocytes or intestinal epithelial cell lines. Besides, in vitro
mast cell degranulation can be detected and quantified by measuring histamine or β-hexosaminidase
release to culture medium [118]. On the other hand, in vivo studies using animal models such as IL-9
transgenic mice [76], Cre/loxP mast cell-deficient mice [119] or mast cell knock-out rats [45] can also
reveal the role of mast cells in the intestinal mucosa. Furthermore, mast cell-dependent changes in
barrier function or motility can be evaluated by electrophysiological measurements in ex vivo tissue
specimens mounted in Ussing chambers or in an organ bath for the assessment of muscle contractility.
In this setting, a pharmacological approach can be designed in which activation/blockade can help to
reveal the effect of mast cells on molecule transport across the epithelial barrier or muscle contractility.
Finally, a correlation study is essential for linking clinical manifestations, digestive dysfunction and
mast cell activation [120].
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7. The Role of Mast Cells in Digestive Disease
7.1. Food Allergy
Mast cells are the main effector participant in allergic responses as a result of a series of
interactions among T cells, B cells, antigen-presenting cells and IgE production. Food allergy can
be classified, depending on the nature of the immune response, as IgE-mediated, non-IgE-mediated
or mixed [121], with mast cells being implicated in both types of response. Patients with food
allergy display a high concentration of mast cell mediators such as histamine, TNF-α, IL-5 and
tryptase in serum, urine, gut lavage fluid, stool and intestinal biopsies [122,123]. As mucosal mast
cell activation increases intestinal permeability, mast cells can also contribute to the initiation of
food allergic inflammation through a greater influx of allergens and microbes to the lamina propria.
In fact, the ion secretion associated with intestinal anaphylaxis has been mainly attributed to mast
cells [124]. Furthermore, the involvement of neuro-immune interactions has been reported in allergic
disease [125,126], demonstrating that neurons communicate and regulate mast cell activation during
allergic inflammation and, in turn, mast cells, reciprocally, stimulate nerve endings. Mast cells
are involved in gastrointestinal and systemic manifestations of food allergy. However, systemic
anaphylaxis has been linked only with connective tissue mast cells, and gastrointestinal food allergy
has been related to both connective tissue and mucosal mast cells. Thus, although it seems clear that
mast cells are essential effectors in food allergy, it is not fully known why allergen exposure can trigger
these different clinical manifestations, thereby underlining mast cell heterogeneity as an essential
contributor to these differences [127]. Nevertheless, little is known of the mechanisms leading to
sensitization to food allergens. IL-9 transgenic mice showed that IL-9-mediated mast cell responses
play an important role in food allergy and oral antigen sensitisation [76]. Therefore, apart from
a pro-inflammatory role, mast cells also modulate allergic sensitisation and downregulate allergic
inflammation [128], dual roles that impact on allergic responses and warrant further study.
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7.2. Inflammatory Bowel Disease
IBD includes two main entities, ulcerative colitis (UC) and Crohn’s disease (CD), in which
chronic gut inflammation results from altered host-microbial interactions in genetically-susceptible
individuals [129]. The contribution of mast cells to IBD has been demonstrated in human and
experimental studies [130] in which increased numbers of mast cells were found in tissue specimens
from both UC and CD patients [131–133], showing ultrastructural changes with evidence of piecemeal
and anaphylactic degranulation. Different types of mast cell mediators involved in IBD pathogenesis
include TNF-α, IL-6, SP, histamine, prostaglandins and leukotrienes [134–137]. Altered brain-gut
interactions have also been detected in IBD [138] and mast cells are thought to play a part in the
neural inflammation present in these patients [139]. In fact, in the DSS experimental model of colitis,
the number of mucosal mast cells in close proximity to VIP nerves was significantly increased [140].
Moreover, alterations in intestinal ion transport [141], the fibrotic response in CD [142,143], microbiota
dysbiosis [144], fibroblast proliferation, collagen production and contractile activity have also been
associated with intestinal mast cell activation [145]. The participation of mast cells in IBD is undeniable,
since they play a role in several aspects of the disease, among which intestinal permeability, initiation
and maintenance of inflammatory processes (with ensuing tissue remodelling) and transmittance of
signals during neuropathological stress [146] are noteworthy. Therefore, mast cell-stabilising drugs or
drugs interfering with mast cell mediators are considered an additional therapeutic possibility in the
treatment of IBD [147].
7.3. Coeliac Disease
Coeliac disease is a chronic inflammatory disorder in the small intestine caused by intolerance
to gluten. It implies remodelling of the intestinal mucosa where immune cells accumulate as a
consequence of both adaptive and innate immune responses to undigested gliadin peptides [148].
A relationship between mast cells and coeliac disease has been reported, showing increased numbers
of mast cells and their mediator histamine in the small intestine [149]. Moreover, the jejunum of
coeliac disease patients shows inflammation caused by histamine, together with albumin secretion,
resulting from endothelial disruption, which facilitates mucosal leakage [150]. Mast cells have been
found to directly react to gliadin fragments by releasing proinflammatory mediators, and have been
associated with increased neutrophil accumulation, prevalence of M1 macrophages, and severity of
tissue damage during onset and progression of the disease [151]. Hence, mucosal mast cell count has
been suggested as a marker for monitoring coeliac disease severity and a target for re-establishing gut
tolerance to gluten.
7.4. Irritable Bowel Syndrome
IBS is a functional gastrointestinal disorder for which, despite intensive research, no biomarker
has been identified to date. In the intestinal mucosa of IBS patients, a low-grade inflammatory infiltrate,
characterised by an increased number of mucosal mast cells and T lymphocytes, has been reported
in all clinical IBS subtypes in the small and large intestine [152]; however, not all studies reported
similar results [153]. Despite disparities in immune cell counts among studies, altered intestinal barrier
with increased epithelial permeability and disruption of TJ appeared to be a common finding [154].
The loss of functional integrity may facilitate the uncontrolled flux of antigens (food, microorganisms,
toxins, etc) across the epithelium and stimulation of immunological responses in the lamina
propria [155], thereby further increasing paracellular epithelial permeability and promoting low-grade
mucosal inflammation. As tryptase is implicated in intestinal barrier deregulation, the generation of
gastrointestinal motor abnormalities and visceral pain [116,156], mast cell activation may be of greater
importance than number, as tryptase production, and not cell counts, correlates with TJ disruption
and clinical symptoms, at least in the small intestine of IBS-D [116]. Moreover, the number of colonic
mucosal mast cells in proximity to nerves positively correlates with abdominal pain severity in
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IBS [157]. Since mast cells form a link between the brain and the gut by local neuro-immune interaction,
they mediate mucosal responses to central stimuli such as psychological stress, thanks to their location
near nerve fibres and the presence of receptors for CRF or SP. Remarkably, the high prevalence of
psychiatric comorbidities in patients with gastrointestinal disorders [158] highlights the significance of
stress in the aetiopathogenesis of IBS. On these lines, recent research revealed associations between
immune activation (humoral activity) and psychiatric comorbidities [159] and between stress episodes
and the initiation/exacerbation of functional gastrointestinal disorders [160]. Evidence of mast cell
implication in IBS pathophysiology is also supported by studies identifying an improvement in gut
symptoms after administration of the stabiliser disodium chromoglycate [24,161,162] or ketotifen,
a histamine H1-receptor antagonist and mast cell stabiliser, which led to reduced visceral perception,
particularly in hypersensitive IBS patients [163].
7.5. Functional Dyspepsia
FD, one of the most common functional gastrointestinal disorders, is characterised by a diversity
of symptoms occurring in the epigastric region. As with IBS, no biomarker has been identified,
despite an increased number of mast cells and eosinphils being observed in the duodenal [164] and
gastric [165,166] mucosa together with epithelial barrier dysfunction. Moreover, a recent meta-analysis
confirmed this previous evidence [167]. Notably, in FD, there is a higher number of mucosal mast cells
with an activated phenotype; however, this finding does not appear to correlate with the impaired
barrier integrity observed in duodenal mucosa [25]. Despite these results, evidence still suggests
that mast cell activation may play a role in the pathophysiology of FD, since granule morphology
significantly differed when FD and control mucosal mast cells were compared, suggesting a differential
synthesis and storage of mediators in mast cell granules [25]. Therefore, further studies are required to
elucidate the role of mast cells in this disorder.
7.6. Mast Cell Activation Disorder
Mast cell activation disorders cover a wide range of entities, from relatively common IgE-mediated
disease and chronic urticaria to rarer conditions such as mastocytosis or monoclonal mast cell activation
disorder. Patients with symptoms stemming from a mast cell activation disorder, which do not meet the
criteria for anaphylaxis, are considered for the diagnosis of mast cell activation syndrome, a condition
for which gastrointestinal symptoms are well documented [168]. In fact, the symptoms have been
considered as secondary to mast cell infiltration of the gut, in addition to deregulation of the local
release of mast cell mediators such as histamine, prostaglandin, gastrin, SP and VIP [169–174]. The most
common symptoms are abdominal pain, nausea/vomiting, diarrhoea, gastrointestinal bleeding and
visceromegaly [174]. However, it remains unclear whether these symptoms arise from locally activated
mast cells or mediators derived from sites distant from the gastrointestinal tract. Further studies are
needed to improve understanding in this field.
8. Concluding Remarks
In summary, mucosal mast cells contribute to homeostasis and are actively involved in a variety of
gastrointestinal diseases. Considering the heterogeneity of digestive entities to which mast cells
contribute, it is indisputable that mast cells are able to influence and regulate gastrointestinal
function through different mechanisms. In this context, the role mast cells play in epithelial
barrier function maintenance, neuro-immune interaction and the regulation of mucosal immunity is
remarkable. Therefore, considering the available data, future therapy approaches to stabilising mast
cells constitute a promising tool for the improvement in gastrointestinal disorders associated with
altered barrier function.
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